| An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation B Schoeberl, AC Faber, D Li, MC Liang, K Crosby, M Onsum, ... Cancer research 70 (6), 2485-2494, 2010 | 334 | 2010 |
| Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors DC Kirouac, JY Du, J Lahdenranta, R Overland, D Yarar, V Paragas, ... Science signaling 6 (288), ra68-ra68, 2013 | 127 | 2013 |
| A mathematical model for neutrophil gradient sensing and polarization M Onsum, CV Rao PLoS computational biology 3 (3), e36, 2007 | 123 | 2007 |
| Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients MD Onsum, E Geretti, V Paragas, AJ Kudla, SP Moulis, L Luus, ... The American journal of pathology 183 (5), 1446-1460, 2013 | 103 | 2013 |
| Model discrimination using data collaboration R Feeley, M Frenklach, M Onsum, T Russi, A Arkin, A Packard The Journal of Physical Chemistry A 110 (21), 6803-6813, 2006 | 83 | 2006 |
| HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B DC Kirouac, J Du, J Lahdenranta, MD Onsum, UB Nielsen, B Schoeberl, ... PLoS computational biology 12 (4), e1004827, 2016 | 68 | 2016 |
| Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis YH Kim, HM Prince, S Whittaker, SM Horwitz, M Duvic, O Bechter, ... European Journal of Cancer 148, 411-421, 2021 | 61 | 2021 |
| Numerical computation of diffusion on a surface P Schwartz, D Adalsteinsson, P Colella, AP Arkin, M Onsum Proceedings of the National Academy of Sciences 102 (32), 11151-11156, 2005 | 61 | 2005 |
| Calling heads from tails: the role of mathematical modeling in understanding cell polarization MD Onsum, CV Rao Current opinion in cell biology 21 (1), 74-81, 2009 | 55 | 2009 |
| Bi-specific fusion proteins U Nielsen, T Wickham, B Schoeberl, B Harms, B Linggi, M Onsum, ... US Patent 9,238,080, 2016 | 48 | 2016 |
| Response to brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma D Jagadeesh, S Horwitz, NL Bartlett, Y Kim, E Jacobsen, M Duvic, M Little, ... The Oncologist 27 (10), 864-873, 2022 | 45 | 2022 |
| Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology DC Kirouac, MD Onsum CPT: pharmacometrics & systems pharmacology 2 (9), 1-7, 2013 | 37 | 2013 |
| Morphology matters in immune cell chemotaxis: membrane asymmetry affects amplification MD Onsum, K Wong, P Herzmark, HR Bourne, AP Arkin Physical biology 3 (3), 190, 2006 | 31 | 2006 |
| Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response B Schoeberl, B Harms, FD GIBBONS, JB FITZGERALD, MD ONSUM, ... US Patent App. 12/707,521, 2011 | 25 | 2011 |
| Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. D Jagadeesh, SM Horwitz, NL Bartlett, RH Advani, ED Jacobsen, M Duvic, ... Journal of Clinical Oncology 37 (15_suppl), 7543-7543, 2019 | 21 | 2019 |
| Bi-specific fusion proteins for tissue repair U Nielsen, T Wickham, B Schoeberl, B Harms, B Linggi, M Onsum, ... US Patent 8,691,771, 2014 | 19 | 2014 |
| Methods and systems for predicting response of cells to a therapeutic agent B Schoeberl, B Harms, FD GIBBONS, JB FITZGERALD, MD ONSUM, ... US Patent 8,623,592, 2014 | 12 | 2014 |
| MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer. B Zhang, J Lahdenranta, J Du, D Kirouac, S Nguyen, R Overland, ... Cancer Research 73 (8_Supplement), 4633-4633, 2013 | 12 | 2013 |
| Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors CS Denlinger, VL Keedy, JM Cleary, W Kubasek, M Onsum, S Moulis, ... Cancer Research 71 (8_Supplement), LB-410-LB-410, 2011 | 12 | 2011 |
| Overcoming resistance to erbb pathway inhibitors G Garcia, W Kubasek, MJ Lahdenranta, G MacBeath, C McDonagh, ... US Patent App. 14/004,848, 2015 | 11 | 2015 |
